Agenus (NASDAQ:AGEN) told shareholders at its 2026 virtual annual meeting that it remains focused on advancing its ...

The safety run-in enrolled patients with non-metastatic solid tumors, divided into two cohorts of 10 patients each: dMMR/MSI-H and pMMR/MSS. Patients received a single dose of BOT (25 mg or 50 mg) ...

LEXINGTON, Mass., April 01, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that the first patient has been enrolled in the landmark global ...

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today shared new data on botensilimab (BOT) and balstilimab (BAL) at the American Society of Clinical ...

LEXINGTON, Mass., April 03, 2026--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today announced that data from an investigator-initiated Phase II trial conducted ...

Logo courtesy Bot Image Inc. The Omaha-based MRI medical device company, Bot Image Inc., announced this month an addition to its line of software products aimed at assisting the detection of prostate ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (NASDAQ: AGEN), a leader in developing novel immunological agents to treat various cancers, today announced the results of its end-of-Phase 2 (EOP2) ...

CAMBRIDGE, Mass., May 26, 2023 /PRNewswire/ -- The Eureka Clinical AI platform, from ConcertAI's TeraRecon, the advanced visualization and clinical AI SaaS category leader, now provides clinicians ...

OMAHA, Neb. and BELGRADE, Maine, Sept. 25, 2023 /PRNewswire/ -- Prostate cancer management reached a new pinnacle of precision with Bot Image's ProstatID using Bi-parametric MRI (bpMRI). The Nebrasksa ...

LEXINGTON, Mass.--(BUSINESS WIRE)--Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today announced that data from the investigator sponsored NEOASIS study were presented in an oral session at ...